Subject: patient safety | sub_nursing | interface issues | evidence based practice | guidelines | Research Papers | sub_pharmacyandpharmacology | interprofessional issues | Research Paper
Rationale, aims and objectives \ud There is widespread use of unlicensed medicines within primary and secondary care but little information is available around how these medicines are used. This analysis examines and evaluates the content and quality of relevant guidanc... View more
 Association of Pharmaceutical Specials Manufacturers. The Specials Industry 2017.
 British Medical Association, Royal Pharmaceutical Society. Special-order Manufacturers 2014.
 Donovan G, Parkin L, Wilkes S. Special unlicensed medicines: what we do and do not know about them. Br J Gen Pract 2015;65:e861. doi:10.3399/bjgp15X688033.
 NHS Business Services Authority. CCG Data - Prescribing of and spending on special order products. NHS Bus Serv Auth 2017. https://www.nhsbsa.nhs.uk/prescription-data/prescribing15          data/information-services-volume-and-cost-special-order-products (accessed July 19, 2017).
Medicines and Healthcare Products Regulatory Agency. The supply of unlicensed medicinal products (“specials”) MHRA Guidance Note 14 2014.
https://www.tga.gov.au/accessing-unapproved-products (accessed July 27, 2017).
European Community. DIRECTIVE 2001/83/EC ON THE COMMUNITY CODE RELATING TO MEDICINAL PRODUCTS FOR HUMAN USE as amended by Directive 2002 / 98 / EC of the European Parliament and of the Council of 27 January. Off J Eur Union 2004:67-128.